Investors

Overview

Corporate Profile

Gamida Cell is an advanced cell therapy company committed to finding cures for patients with cancer and other serious diseases. We harness our NAM-enabled technology platform to create therapies with the potential to improve the course of cancer care.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

View All
May 31, 2023

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

Read More
May 31, 2023

Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting

Read More
May 22, 2023

Gamida Cell Appoints Terry Coelho as CFO

Read More
May 15, 2023

Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update

Read More
May 11, 2023

Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast

Read More
Apr 19, 2023

Gamida Cell Announces Pricing of $23 Million Public Offering of Securities

Read More
Apr 18, 2023

Gamida Cell Announces Launch of Public Offering of Securities

Read More
Apr 17, 2023

Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval

Read More
Mar 27, 2023

Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update

Read More
Mar 20, 2023

Gamida Cell Announces Changes to Board of Directors

Read More
Mar 20, 2023

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast

Read More
Mar 07, 2023

Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference

Read More
Feb 18, 2023

Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR

Read More
Dec 12, 2022

Gamida Cell Announces Closing of $25 Million Financing With Highbridge

Read More
Nov 23, 2022

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

Read More
Nov 21, 2022

Gamida Cell Provides Regulatory Update on Omidubicel

Read More
Nov 14, 2022

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

Read More
Nov 10, 2022

Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference

Read More
Nov 07, 2022

Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast

Read More
Nov 07, 2022

GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers

Read More
Corporate Fact Sheet
More information is coming soon.
Corporate Presentation
More information is coming soon.

Investor & Media Contact

Ryan Pugliares
Gamida Cell Ltd.
IRPR@gamida-cell.com